MedPath
HSA Approval

COMTAN TABLET 200 mg

SIN11234P

COMTAN TABLET 200 mg

COMTAN TABLET 200 mg

November 29, 1999

ORION PHARMA (SG) PTE. LTD.

ORION PHARMA (SG) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantORION PHARMA (SG) PTE. LTD.
Licence HolderORION PHARMA (SG) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION** Entacapone should only be used in combination with levodopa/benserazide or levodopa/carbidopa. The prescribing information for these levodopa preparations is applicable to their concomitant use with entacapone. **Posology** One 200 mg tablet is taken with each levodopa/dopa decarboxylase inhibitor dose. The maximum recommended dose is 200 mg ten times daily, i.e. 2,000 mg of entacapone. Entacapone enhances the effects of levodopa. Hence, to reduce levodopa-related dopaminergic adverse reactions, e.g. dyskinesias, nausea, vomiting and hallucinations, it is often necessary to adjust levodopa dosage within the first days to first weeks after initiating entacapone treatment. The daily dose of levodopa should be reduced by about 10 to 30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient. Entacapone increases the bioavailability of levodopa from standard levodopa/benserazide preparations slightly more (5 to 10%) than from standard levodopa/carbidopa preparations. Hence, patients who are taking standard levodopa/benserazide preparations may need a larger reduction of their levodopa dose when entacapone is initiated. If entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. Renal impairment does not affect the pharmacokinetics of entacapone and there is no need for dose adjustment. However, for patients who are receiving dialysis therapy, a longer dosing interval may be considered (see section PHARMACOKINETICS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hepatic impairment: see section CONTRAINDICATIONS **Elderly** No dosage adjustment of entacapone is required for elderly patients. **Children** Comtan is not recommended for use in children below age 18 due to lack of data on safety and efficacy. **Method of administration** Entacapone is administered orally and simultaneously with each levodopa/carbidopa or levodopa/benserazide dose. Entacapone can be taken with or without food (see section PHARMACOKINETICS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

ORAL

Medical Information

**INDICATIONS** Entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with Parkinson’s disease and end-of-dose motor fluctuations, who cannot be stabilized on those combinations.

**CONTRAINDICATIONS** Hepatic impairment. Patients with pheochromocytoma due to the increased risk of hypertensive crisis. A previous history of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis. Concomitant use of entacapone and non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine). Concomitant use of a selective MAO-A inhibitor plus a selective MAO-B inhibitor and entacapone (see section INTERACTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Known hypersensitivity to entacapone or to any of the excipients.

N04BX02

entacapone

Manufacturer Information

ORION PHARMA (SG) PTE. LTD.

Orion Corporation, Orion Pharma

Orion Corporation, Orion Pharma (Primary and Secondary Packager)

Active Ingredients

ENTACAPONE

200 mg

Entacapone

Documents

Package Inserts

Comtan Tablet 200mg PI.pdf

Approved: April 1, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.